Skip to main content

Table 2 Prevalence of maternal P. falciparum parasitaemia in Malawian women given IFA, MMN and LNSa

From: Providing lipid-based nutrient supplement during pregnancy does not reduce the risk of maternal P falciparum parasitaemia and reproductive tract infections: a randomised controlled trial

Outcome IFA MMN LNS LNS vs. IFA LNS vs. MMN MMN vs. IFA
P. falciparum parasitaemia at 32 gw (RDT) 12.0 (8.7–15.3) (374)a 9.5 (6.6–12.5) (377) 10.9 ( 7.7–14.2) (357) 0.91 (0.61–1.36) 1.14 (0.74–1.76) 0.79 (0.52–1.20)
P. falciparum parasitaemia at 36 gw (PCR) 10.8 (7.5–14.1) (352) 8.5 (5.6–11.4) (363) 7.6 (4.8–10.4) (355) 0.70 (0.44–1.13) 0.89 (0.54–1.46) 0.79 (0.50–1.24)
P. falciparum parasitaemia at delivery (RDT) 9.1 (6.2–12.0) (373) 7.8 (5.1–10.5) (372) 8.0 (5.3–10.8) (386) 0.88 (0.55–1.40) 1.03 (0.63–1.67) 0.86 (0.53–1.37)
P. falciparum parasitaemia at delivery (PCR) 20.6 (16.5–24.7) (369) 22.4 (18.0–26.8) (357) 17.6 (13.7–21.5) (369) 0.86 (0.63–1.15) 0.79 (0.59–1.05 1.09 (0.82–1.44)
  1. aValues are percentages (95% CIs) (n) or risk ratios (95% CIs). IFA iron folic acid, MMN multiple micronutrients, LNS lipid based nutrient supplements, RDT rapid diagnostic testing, PCR polymerase chain reaction